Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings

Clin Pharmacol Ther. 1989 Jul;46(1):78-81. doi: 10.1038/clpt.1989.109.

Abstract

The pharmacokinetics of a single oral dose of 6 mg perphenazine was studied in a group of six slow and six rapid hydroxylators of debrisoquin. Peak serum concentrations of perphenazine were significantly higher in slow hydroxylators than they were in rapid hydroxylators (2.4 +/- 0.6 versus 0.7 +/- 0.3 nmol/L, p less than 0.001). The AUC(0-12) was also higher in slow hydroxylators than it was in rapid hydroxylators (18.5 +/- 6.2 versus 4.5 +/- 2.5 nmol.L-1.hr, p less than 0.001). The data suggest that the disposition of the antipsychotic drug perphenazine covaries with polymorphic debrisoquin hydroxylation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Adult
  • Debrisoquin / metabolism*
  • Female
  • Humans
  • Hydroxylation
  • Isoquinolines / metabolism*
  • Male
  • Perphenazine / pharmacokinetics*
  • Polymorphism, Genetic

Substances

  • Isoquinolines
  • Perphenazine
  • Debrisoquin